EMMA Emmaus Life Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.0%
TTM net income YoY-77.9%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR-18.2%
Net income 3-yr CAGR—
Margins
Gross margin93.6%
Operating margin29.3%
Net margin-38.8%
FCF margin—
EBITDA margin29.7%
Returns
ROE—
ROA-30.3%
ROIC (approx.)—
Asset turnover0.78x
Leverage & solvency
Liabilities / assets504.3%
Debt / equity—
Current ratio0.09x
Interest coverage0.57x
Cash quality & payout
Operating cash flow / net income-0.66x
Accruals ratio-50.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.32M | $1.98M | $3.85M | $3.38M | $2.82M | $2.41M | $3.29M | $5.48M |
| Cost of revenue | $344,000 | $168,000 | $235,000 | $247,000 | $150,000 | $225,000 | $309,000 | $394,000 |
| Gross profit | $5.97M | $1.81M | $3.62M | $3.13M | $2.67M | $2.18M | $2.98M | $5.08M |
| R&D expense | $116,000 | $40,000 | $31,000 | $50,000 | $56,000 | $176,000 | $137,000 | $146,000 |
| SG&A expense | $1.57M | $1.85M | $1.80M | $1.73M | $2.31M | $2.34M | $2.29M | $2.80M |
| Operating income | $3.79M | -$823,000 | $886,000 | $695,000 | -$370,000 | -$980,000 | -$557,000 | $821,000 |
| Interest expense | $1.60M | $2.13M | $2.27M | $1.93M | $1.68M | $1.26M | $1.28M | $1.34M |
| Pretax income | $1.34M | -$3.33M | -$1.94M | -$1.50M | -$1.73M | -$2.33M | -$1.74M | $1.83M |
| Income tax | -$1,000 | $4,000 | $16,000 | $579,000 | -$590,000 | $4,000 | $6,000 | -$1,000 |
| Net income | $1.34M | -$3.33M | -$1.95M | -$2.08M | -$1.14M | -$2.33M | -$1.75M | $1.83M |
| EBITDA | $3.81M | -$808,000 | $901,000 | $710,000 | -$366,000 | -$975,000 | -$552,000 | $826,000 |
| EPS (basic) | 0.02 | -0.05 | — | -0.03 | -0.02 | -0.04 | — | 0.03 |
| EPS (diluted) | 0.02 | -0.05 | — | -0.03 | -0.02 | -0.04 | — | 0.03 |
| Weighted avg. shares (diluted) | 120.54M | 70.19M | — | 63.87M | 63.87M | 63.87M | — | 63.87M |
| Balance sheet | ||||||||
| Cash & equivalents | $2.81M | $1.07M | $2.13M | $293,000 | $886,000 | $1.33M | $1.39M | $1.25M |
| Receivables | $709,000 | $2.05M | $2.80M | $2.62M | $2.07M | $2.06M | $2.62M | $4.94M |
| Inventory | $1.59M | $1.91M | $1.55M | $1.21M | $1.31M | $1.44M | $1.64M | $1.61M |
| Current assets | $6.00M | $6.00M | $7.75M | $4.79M | $5.01M | $5.65M | $6.77M | $9.20M |
| PP&E, net | $86,000 | $98,000 | $113,000 | $128,000 | $143,000 | $41,000 | $46,000 | $49,000 |
| Total assets | $16.37M | $18.70M | $21.44M | $20.76M | $23.34M | $22.48M | $23.60M | $27.34M |
| Current liabilities | $66.12M | $70.54M | $69.07M | $64.17M | $62.08M | $64.92M | $63.55M | $64.13M |
| Long-term debt | $24.99M | $26.56M | $27.13M | $29.07M | $29.73M | $29.01M | $28.96M | $29.30M |
| Total debt | $24.99M | $26.56M | $27.13M | $29.07M | $29.73M | $29.01M | $28.96M | $29.30M |
| Total liabilities | $82.55M | $86.56M | $85.04M | $80.24M | $79.05M | $81.08M | $80.08M | $81.12M |
| Shareholders' equity | -$66.18M | -$67.86M | -$63.61M | -$59.49M | -$55.70M | -$58.60M | -$56.48M | -$53.78M |
| Net debt | $22.18M | $25.49M | $25.00M | $28.78M | $28.85M | $27.67M | $27.58M | $28.04M |
| Shares outstanding | 70.19M | 70.19M | 70.19M | 63.87M | 63.87M | 63.87M | 63.87M | 63.87M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.69M | -$344,000 | $2.21M | $409,000 | -$2.91M | $279,000 | $343,000 | $148,000 |
| Capital expenditure | — | — | $0 | $0 | — | — | $6,000 | -$1,000 |
| Free cash flow | — | — | $2.21M | $409,000 | — | — | $337,000 | $149,000 |
| Investing cash flow | $1.58M | $0 | $0 | $0 | $2.17M | $0 | -$2,000 | $1,000 |
| Financing cash flow | -$1.53M | -$702,000 | -$362,000 | -$1.00M | $284,000 | -$345,000 | -$195,000 | -$438,000 |
| Depreciation & amortization | $14,000 | $15,000 | $15,000 | $15,000 | $4,000 | $5,000 | $5,000 | $5,000 |
| Stock-based compensation | $0 | $1,000 | $7,000 | $9,000 | -$1,000 | $10,000 | $29,000 | $28,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.